Supplementary Data1 from Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma | Synapse
September 3, 2024Open Access
Supplementary Data1 from Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma
Key Points
Key points are not available for this paper at this time.
Abstract
Table S1 Table S2 added (Representativeness of Study Participants), Figures S1 to S3 Figure S4 added to replace data not shown in the main text